Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1220P - Proposals for revision of N descriptors in the forthcoming edition of TNM staging for NSCLC

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Xiaoling Shang

Citation

Annals of Oncology (2020) 31 (suppl_4): S735-S743. 10.1016/annonc/annonc282

Authors

X. Shang1, H. Wang2

Author affiliations

  • 1 Clinical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Scienses, 250117 - Jinan/CN
  • 2 Internal-medicine Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Scienses, 250117 - Jinan/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1220P

Background

The current pathological nodal (pN) stage is incomplete for distinguishing heterogeneous pN1 and pN2 disease well for patients with non-small cell lung cancer (NSCLC). We performed a large retrospective study to incorporate the number of lymph nodes (nN) into TNM classification using data from the Surveillance Epidemiology and End Results (SEER) database and further validated its feasibility using data from Shandong Cancer Hospital and Shandong Provincial Hospital.

Methods

A training cohort of 5779 and 8231 NSCLC patients from the SEER database were collected in this study. Concurrently, a validation cohort of 385 NSCLC patients from Shandong Cancer Hospital and Shandong Provincial Hospital were also included. The X-tile model was used to determine the optimal cutoff value of nN. Kaplan-Meier and log-rank tests were used to compare survival differences. The multivariate Cox proportional hazards regression model was used to analyse the influence of pN staging on overall survival (OS).

Results

According to the optimal cutoff value of nN, we classified patients into three nN categories (nN0; nNa: nN1-4; nNb: nN4-). Data from the training cohort indicated that survival curves were better in patients with pN2a compared to those with pN1b (P < 0.001). The multivariate Cox analysis also revealed that patients with pN1b and pN2a had no significant difference in OS (pN2a VS. pN1b: HR=0.926; 95%CI: 0.774-1.109; P = 0.406). The modified TNM staging based on the location and number of lymph nodes was used for further analysis. Survival curves of modified pN1 and pN2 were well distributed compared with the current TNM staging in the training cohort (P < 0.001) and the validation cohort (P = 0.049).

Conclusions

The modified TNM staging combined locational pN stage and numerical nN stage and was a more accurate prognostic determinant in NSCLC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.